Rasna Therapeutics, Inc. (RASP)
USD 0.0
(900.0%)
USD 0.0
(900.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 95.65 Thousand USD | 12.17% |
| 2022 | 85.27 Thousand USD | 91.3% |
| 2021 | 44.57 Thousand USD | 35.31% |
| 2020 | 32.94 Thousand USD | -99.33% |
| 2019 | 4.94 Million USD | -5.35% |
| 2018 | 5.22 Million USD | -42.45% |
| 2017 | 9.07 Million USD | 3505405.02% |
| 2016 | 259.00 USD | -32.73% |
| 2015 | 385.00 USD | -94.24% |
| 2014 | 6685.00 USD | -85.58% |
| 2013 | 46.34 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 48.61 Thousand USD | 85.73% |
| 2024 Q1 | 26.17 Thousand USD | -72.64% |
| 2023 Q2 | 52.29 Thousand USD | -13.67% |
| 2023 FY | 95.65 Thousand USD | 12.17% |
| 2023 Q1 | 60.57 Thousand USD | -28.96% |
| 2023 Q4 | 95.65 Thousand USD | 158.11% |
| 2023 Q3 | 37.06 Thousand USD | -29.14% |
| 2022 Q1 | 33.45 Thousand USD | -24.95% |
| 2022 FY | 85.27 Thousand USD | 91.3% |
| 2022 Q4 | 85.27 Thousand USD | 18.65% |
| 2022 Q3 | 71.86 Thousand USD | 101.33% |
| 2022 Q2 | 35.69 Thousand USD | 6.7% |
| 2021 Q1 | 3351.00 USD | -89.83% |
| 2021 FY | 44.57 Thousand USD | 35.31% |
| 2021 Q3 | 94.65 Thousand USD | 1.12% |
| 2021 Q2 | 93.6 Thousand USD | 2693.4% |
| 2021 Q4 | 44.57 Thousand USD | -52.91% |
| 2020 Q1 | 4.9 Million USD | -0.73% |
| 2020 Q4 | 32.94 Thousand USD | -98.52% |
| 2020 FY | 32.94 Thousand USD | -99.33% |
| 2020 Q3 | 2.22 Million USD | -55.03% |
| 2020 Q2 | 4.94 Million USD | 0.68% |
| 2019 Q2 | 5.03 Million USD | -2.44% |
| 2019 Q1 | 5.16 Million USD | -1.18% |
| 2019 Q3 | 4.99 Million USD | -0.88% |
| 2019 Q4 | 4.94 Million USD | -0.96% |
| 2019 FY | 4.94 Million USD | -5.35% |
| 2018 FY | 5.22 Million USD | -42.45% |
| 2018 Q4 | 5.22 Million USD | 1.14% |
| 2018 Q3 | 5.16 Million USD | -7.28% |
| 2018 Q2 | 5.57 Million USD | -12.36% |
| 2018 Q1 | 6.35 Million USD | -16.07% |
| 2017 Q4 | 7.57 Million USD | -8.67% |
| 2017 Q1 | 9.97 Million USD | 14.16% |
| 2017 Q2 | 9.07 Million USD | -8.96% |
| 2017 Q3 | 8.29 Million USD | -8.64% |
| 2017 FY | 9.07 Million USD | 3505405.02% |
| 2016 Q4 | 8.73 Million USD | 3373112.36% |
| 2016 Q2 | 484.00 USD | 0.0% |
| 2016 Q1 | 484.00 USD | -76.76% |
| 2016 Q3 | 259.00 USD | -46.49% |
| 2016 FY | 259.00 USD | -32.73% |
| 2015 Q4 | 2083.00 USD | 441.04% |
| 2015 Q2 | 2072.00 USD | 71.52% |
| 2015 FY | 385.00 USD | -94.24% |
| 2015 Q3 | 385.00 USD | -81.42% |
| 2015 Q1 | 1208.00 USD | -68.46% |
| 2014 Q4 | 3830.00 USD | -42.71% |
| 2014 Q2 | 21.17 Thousand USD | -16.36% |
| 2014 Q1 | 25.31 Thousand USD | 0.0% |
| 2014 FY | 6685.00 USD | -85.58% |
| 2014 Q3 | 6685.00 USD | -68.43% |
| 2013 FY | 46.34 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -4040.996% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 95.115% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 99.094% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 82.675% |
| Rebus Holdings, Inc. | 5000.00 USD | -1813.14% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.927% |
| Qrons Inc. | 420.00 USD | -22675.476% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 87.587% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 99.658% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | 80.095% |
| Skye Bioscience, Inc. | 11.94 Million USD | 99.199% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 99.754% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 98.675% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -25.281% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.911% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 93.32% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -32.187% |
| Mesoblast Limited | 667.9 Million USD | 99.986% |
| Marizyme, Inc. | 22.01 Million USD | 99.565% |
| Genus plc | 1.02 Billion USD | 99.991% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 92.958% |
| Pharming Group N.V. | 462.85 Million USD | 99.979% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 97.113% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 80.832% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 84.744% |
| ContraFect Corporation | 20.67 Million USD | 99.537% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | 75.496% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | 74.97% |
| IMV Inc. | 31.33 Million USD | 99.695% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 97.693% |
| MultiCell Technologies, Inc. | 126.22 USD | -75685.929% |
| ONE Bio Corp. | 70.08 Million USD | 99.864% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 89.82% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.926% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | 77.843% |
| Q BioMed Inc. | 3.51 Million USD | 97.279% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 99.728% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | 63.389% |
| Biomind Labs Inc. | 73.81 Thousand USD | -29.583% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.979% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 93.398% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 99.681% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 96.517% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 86.086% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 96.325% |
| GB Sciences, Inc. | 103.44 Thousand USD | 7.526% |
| Alpha Cognition Inc. | 2.45 Million USD | 96.099% |
| HST Global, Inc. | 1526.00 USD | -6168.48% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 90.318% |
| Halberd Corporation | 10.13 Thousand USD | -844.201% |
| Enzolytics Inc. | 361.7 Million USD | 99.974% |
| Agentix Corp. | 261.39 Thousand USD | 63.405% |
| Resverlogix Corp. | 8.11 Million USD | 98.821% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 94.906% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.998% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 99.799% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 85.046% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -319.898% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 98.931% |
| AVAX Technologies, Inc. | 7.37 Million USD | 98.703% |
| Zenith Capital Corp. | 7410.00 USD | -1190.918% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.997% |
| Ember Therapeutics, Inc. | 184.00 USD | -51887.5% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | 70.275% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | 63.401% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 89.692% |
| Kadimastem Ltd | 2.3 Million USD | 95.848% |
| Helix BioMedix, Inc. | 3.02 Million USD | 96.838% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 99.818% |
| BioStem Technologies, Inc. | 14.56 Million USD | 99.343% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -67.543% |
| LadRx Corporation | 2.3 Million USD | 95.855% |
| Cell Source, Inc. | 195.17 Thousand USD | 50.988% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 72.949% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 72.949% |
| NovAccess Global Inc. | 62.24 Thousand USD | -53.671% |
| Affymax, Inc. | 7.44 Million USD | 98.715% |
| Itoco Inc. | 1.4 Million USD | 93.168% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | 9.758% |
| Mobile Lads Corp. | 52.00 USD | -183855.769% |
| CytoDyn Inc. | 11.13 Million USD | 99.141% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | 33.094% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -434.994% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | 75.184% |
| SYBLEU INC | 330.46 Thousand USD | 71.054% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | 76.636% |
| International Stem Cell Corporation | 5.39 Million USD | 98.225% |
| Bioxytran, Inc. | 137.63 Thousand USD | 30.501% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 99.362% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 99.423% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -21.085% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 88.937% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 98.727% |
| Neutra Corp. | 2851.00 USD | -3255.209% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 99.705% |
| PureTech Health plc | 693.97 Million USD | 99.986% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 98.815% |
| IXICO plc | 15.84 Million USD | 99.396% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 98.845% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.907% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Cellectis S.A. | 333.99 Million USD | 99.971% |